These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30811541)

  • 1. Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin.
    Yoshida A; Matsubayashi Y; Nojima T; Suganami H; Abe T; Ishizawa M; Fujihara K; Tanaka S; Kaku K; Sone H
    J Clin Endocrinol Metab; 2019 Sep; 104(9):3647-3660. PubMed ID: 30811541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance.
    Nojima T; Matsubayashi Y; Yoshida A; Suganami H; Abe T; Ishizawa M; Fujihara K; Tanaka S; Kaku K; Sone H
    Diabet Med; 2020 Aug; 37(8):1316-1325. PubMed ID: 32096571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.
    Terauchi Y; Fujiwara H; Kurihara Y; Suganami H; Tamura M; Senda M; Gunji R; Kaku K
    J Diabetes Investig; 2019 Nov; 10(6):1518-1526. PubMed ID: 31033218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
    Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Fujiwara H; Kaku K
    J Diabetes Investig; 2019 Sep; 10(5):1272-1283. PubMed ID: 30702214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status.
    Nunoi K; Sato Y; Kaku K; Yoshida A; Suganami H
    Diabetes Obes Metab; 2019 Jul; 21(7):1715-1724. PubMed ID: 30945431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss.
    Sato Y; Nunoi K; Kaku K; Yoshida A; Suganami H
    Diabetes Obes Metab; 2020 Feb; 22(2):222-230. PubMed ID: 31608549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
    Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Kaku K
    J Diabetes Investig; 2020 Jan; 11(1):132-141. PubMed ID: 31197929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.
    Matsuba R; Matsuba I; Shimokawa M; Nagai Y; Tanaka Y
    Diabetes Obes Metab; 2018 May; 20(5):1311-1315. PubMed ID: 29316197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).
    Utsunomiya K; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Koshida R; Kameda H; Tamura M; Kaku K
    J Diabetes Investig; 2020 Jul; 11(4):906-916. PubMed ID: 32034997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline.
    Tobe K; Suganami H; Kaku K
    J Diabetes Investig; 2018 Jul; 9(4):862-869. PubMed ID: 29032638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
    Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
    Diabetes Obes Metab; 2018 May; 20(5):1176-1185. PubMed ID: 29316236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).
    Utsunomiya K; Koshida R; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Kaku K
    J Diabetes Investig; 2021 Feb; 12(2):184-199. PubMed ID: 32597517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
    Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
    Cardiovasc Diabetol; 2021 Jan; 20(1):4. PubMed ID: 33397376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice.
    Obata A; Kubota N; Kubota T; Iwamoto M; Sato H; Sakurai Y; Takamoto I; Katsuyama H; Suzuki Y; Fukazawa M; Ikeda S; Iwayama K; Tokuyama K; Ueki K; Kadowaki T
    Endocrinology; 2016 Mar; 157(3):1029-42. PubMed ID: 26713783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
    Kaku K; Watada H; Iwamoto Y; Utsunomiya K; Terauchi Y; Tobe K; Tanizawa Y; Araki E; Ueda M; Suganami H; Watanabe D;
    Cardiovasc Diabetol; 2014 Mar; 13():65. PubMed ID: 24678906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study).
    Kaku K; Naito Y; Senda M; Kurihara Y; Gunji R; Kakiuchi S; Utsunomiya K
    J Diabetes Investig; 2020 Mar; 11(2):405-416. PubMed ID: 31390166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
    Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
    Cherney DZI; Cooper ME; Tikkanen I; Pfarr E; Johansen OE; Woerle HJ; Broedl UC; Lund SS
    Kidney Int; 2018 Jan; 93(1):231-244. PubMed ID: 28860019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.